Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01869725 · OUTCOME

Compare Sensitivity of 68Ga-DOTATOC PET/CT With Octreoscan

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT · Source last updated 2021-09-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of sensitivity
Interval / dispersion
Not reported
Time frame
Up to 6 months

What was measured

Compare sensitivity of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors

Analysis population: Patients with neuroendocrine tumor or other somatostatin receptor positive tumor

Groups in this outcome

Diagnostic (Gallium Ga 68-edotreotide PET/CT)

Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed. gallium Ga 68-edotreotide: Given IV positron emission tomography/computed tomography: Undergo gallium Ga 68-edotreotide PET/CT scan indium In 111 pentetreotide: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan computed tomography: Undergo indium In 111 pentetreotide contrast-enhanced CT scan contrast-enhanced magnetic resonance imaging: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Diagnostic (Gallium Ga 68-edotreotide PET/CT)34

Reported measurements

Sensitivity of Ga-68-DOTATOC
Values in percentage of sensitivity · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Diagnostic (Gallium Ga 68-edotreotide PET/CT)96.55Not reportedNot reportedNot reportedNot reported
Sensitivity of OctreoScan
Values in percentage of sensitivity · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Diagnostic (Gallium Ga 68-edotreotide PET/CT)79.31Not reportedNot reportedNot reportedNot reported
Sensitivity of Conventional Imaging (CI)
Values in percentage of sensitivity · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Diagnostic (Gallium Ga 68-edotreotide PET/CT)82.24Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        96.55
    title
    Sensitivity of Ga-68-DOTATOC
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        79.31
    title
    Sensitivity of OctreoScan
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        82.24
    title
    Sensitivity of Conventional Imaging (CI)
denoms
  1. counts
    1. group Id
      OG000
      value
      34
    units
    Participants
description
Compare sensitivity of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors
groups
  1. description
    Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed. gallium Ga 68-edotreotide: Given IV positron emission tomography/computed tomography: Undergo gallium Ga 68-edotreotide PET/CT scan indium In 111 pentetreotide: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan computed tomography: Undergo indium In 111 pentetreotide contrast-enhanced CT scan contrast-enhanced magnetic resonance imaging: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
    id
    OG000
    title
    Diagnostic (Gallium Ga 68-edotreotide PET/CT)
param Type
NUMBER
population Description
Patients with neuroendocrine tumor or other somatostatin receptor positive tumor
reporting Status
POSTED
time Frame
Up to 6 months
title
Compare Sensitivity of 68Ga-DOTATOC PET/CT With Octreoscan
type
PRIMARY
unit Of Measure
percentage of sensitivity

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice